Novozymes A/S (OTCMKTS:NVZMY) Short Interest Up 1,020.0% in December

Novozymes A/S (OTCMKTS:NVZMYGet Free Report) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 5,600 shares, a growth of 1,020.0% from the November 30th total of 500 shares. Based on an average trading volume of 33,000 shares, the days-to-cover ratio is currently 0.2 days.

Novozymes A/S Price Performance

Shares of OTCMKTS NVZMY traded up $0.70 during midday trading on Thursday, hitting $57.71. 13,351 shares of the company’s stock were exchanged, compared to its average volume of 13,140. The stock’s 50 day moving average price is $59.83 and its 200-day moving average price is $63.27. The firm has a market cap of $27.03 billion, a P/E ratio of 36.53, a PEG ratio of 3.87 and a beta of 0.87. Novozymes A/S has a twelve month low of $49.99 and a twelve month high of $72.50.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on NVZMY shares. Citigroup cut Novozymes A/S from a “neutral” rating to a “sell” rating in a research note on Thursday, October 17th. Barclays upgraded Novozymes A/S to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Berenberg Bank raised shares of Novozymes A/S to a “strong-buy” rating in a report on Tuesday, September 24th.

Check Out Our Latest Research Report on NVZMY

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Read More

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.